Conflixis offers an AI-powered risk engine that helps organizations identify and manage conflicts of interest and external influence, promoting trust and transparency in decision-making.

Conflixis

Conflixis | 1,637 followers on LinkedIn. Discover conflicts of interest and outside influence in your organization. | The Conflixis risk engine unlocks the power of external data and internal information to promote trust and transparency at large organizations.

Co-Founder & COO

Vincent Wan

Software Engineer – Rallyware

Kateryna Prokofieva

Director @ Conflixis

Jessica Francis

🚀 🕵♂️ Our Inaugural Open Payments Report is finally here! 🕵♂️ 🚀 We invite you to read the Wall Street Journal's exclusive report coverage: https://lnkd.in/eJmX5-wF In this report, we delve into specific examples and critical questions about industry influence today. We demonstrate how regulators, institutions, and others can use this information to promote transparency and ethical practices in healthcare. Our goal is to provide valuable insights for patients, compliance and legal professionals, policymakers, healthcare providers, and researchers. By identifying and managing conflicts of interest, we aim to help mitigate rising costs and ensure better healthcare outcomes. Download the report now and join us in driving forward transparency and trust in healthcare. https://lnkd.in/eq4EbZzt Feel free to reach out or book a meeting with our team if you have any questions or need further insights. #Conflixis #OpenPayments #HealthcareCompliance #ConflictsOfInterest #HealthcareTransparency #EthicalHealthcare #SupplyChainRisk #ThirdPartyRisk

We're #hiring a new Business Development Representative in Dallas, Texas. Apply today or share this post with your network.

We're #hiring a new Healthcare Conflict Data Scientist in Dallas, Texas. Apply today or share this post with your network.

We're #hiring a new Cloud Infrastructure & Security Engineer in Dallas, Texas. Apply today or share this post with your network.

We're #hiring a new Conflict Data Analyst in Dallas, Texas. Apply today or share this post with your network.

🔍 Continuing our spotlight on Research Integrity! 🔍 Researchers were paid $67 million to learn about drug and device company products--while doing research funded by that company. Of the $260 million drug and device companies paid to researchers in 2023, $67 million was for speaking and attendance at events that are not for continuing education. Learning about new products and technologies is critical—but when the integrity of research is at stake, more scrutiny is justified. If you work at a research institution and are curious about how your researchers are interacting with industry, get in touch. We will identify your risky relationships—for free. Book a demo with us: https://lnkd.in/eKT5R_Rf Download the 2024 Open Payments report: https://lnkd.in/eq4EbZzt #ResearchIntegrity #ConflictOfInterest #ScienceTransparency #Conflixis #HCCA #AAMC #COI

For the next two weeks, Conflixis will be doing spotlight posts on Research Integrity 🔍 Our 2024 Open Payments Report identified numerous researchers who received promotional, consulting, or royalty payments from entities that were funding research they were undertaking in the same twelve-month period. In 2023 alone, researchers received $260 million in non-research-related payments from funders also financing their studies. 💰 Since 2016, this figure totals $2.3 billion. 💰 Despite stringent policies at academic research centers, researchers' financial relationships with funders might compromise research integrity. It's crucial to address these conflicts of interest to ensure unbiased scientific findings and maintain public trust in research. Download your copy of the Open Payments Report here: https://lnkd.in/eq4EbZzt #ResearchIntegrity #ConflictOfInterest #ScienceTransparency

Latest study from Dr. Aaron Mitchell. Keep it up!!

Coming soon! The Conflixis Open Payments Report. Stay tuned.

Metric
Company Name	Conflixis
Symbol
MSH ID	COM:CONFLIXIS
Market	PRIVATE
Sector	Commercial & Professional Services
Industry	Risk Management
Country	US
Stage
Employee Count
Website	conflixis.com
LinkedIn	conflixis
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CONF

COM:CONFLIXIS

Conflixis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue